Merus To Present Petosemtamab Data At ESMO Asia Congress 2024

Merus N.V., a clinical-stage oncology company focused on developing innovative multispecific antibodies (Biclonics® and Triclonics®), announced the publication of an abstract on petosemtamab. Petosemtamab is Biclonics® targeting EGFR and LGR5 to treat recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) in previously treated patients (2L+). The abstract features updated clinical data from both the initial expansion cohort (1500 mg) and a new dose-comparison cohort (1100 mg vs 1500 mg), which will be presented at the European Society for Medical Oncology (ESMO®) Asia Congress 2024 in Singapore, December from 6th to 8th, 2024.

Fabian Zohren, M.D., PhD, Chief Medical Officer of Merus, said in a statement, “Petosemtamab 1500 mg monotherapy continues to demonstrate consistent, durable, and clinically meaningful efficacy in 2L+ r/m HNSCC, underscoring its potential to become a new standard of care. We are looking forward to our upcoming presentation, which will include new information with updated efficacy and safety information for the larger, combined 2L+ dataset.”

A conference call discussing the presentation will take place on December 7 at 9:00 a.m. ET. The call will include interim data from a later data cutoff, incorporating additional evaluable patients and more mature treatment duration information.